



Media release

Ad hoc announcement pursuant to Art. 53 LR

**SHL Telemedicine enters into agreement with Henry Schein, Inc. –
Henry Schein to market SmartHeart™ full 12 lead ECG technology to its US
healthcare customers**

Tel Aviv / Zurich – 31 May 2022 – SHL Telemedicine Ltd. announced today that it has entered into a Marketing Services, Distribution and Supply Agreement with Henry Schein, Inc (“HSI”), according to which HSI will market SHL’s SmartHeart™ technology to healthcare professionals, providers, suppliers, practitioners and other customers of HSI in healthcare markets in the US.

Further information

Fabienne Farner, IRF, Phone: +41 43 244 81 42 farner@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.